Miguel Gonzalez Velez, Medical Oncologist at John Theurer Cancer Center , University Medical Center, shared on X:
“SAFFRON (Phase 3) with osimertinib + savolitinib vs. platinum-doublet chemo in EGFR-mutant, MET-overexpressed/amplified NSCLC after osimertinib. Built on the SACHI Phase 3 data from China.
Take: MET amp is the most common resistance mechanism after 1L osimertinib (~10-24%). We know that dual EGFR blockade is key (MARIPOSA, ORCHARD and others). Likely they will displace chemo regimens soon.
Question remains which combination will be the best?”
Title: Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial
Authors: Shun Lu, Jie Wang, Nong Yang, Dongqing Lv, Lijuan Chen, Lin Wu, Xingya Li, Longhua Sun, Yongfeng Yu, Bo Jin, Lin Yang, Yubiao Guo, Haipeng Xu, Tienan Yi, Aiping Zeng, Xiaorong Dong, Jianhua Chen, Ziping Wang, Hongrui Niu, Ying Cheng, Pinhua Pan, Pengbo Deng, Hongming Pan, Xuhong Min, Jun Bai, Laiyu Liu, Tongmei Zhang, Juan Li, Songhua Fan, Michael M. Shi, Tony Mok, Weiguo Su
You can also explore: CheckMate 77T: ctDNA Clearance and MRD Refine Risk After Perioperative Nivolumab
